Table 3. Secondary and other end‐points at baseline (visit 1) and after treatment with pitavastatin and atorvastatin.

Variable	Baseline (visit 1)	After treatment		P‐value for
		Pitavastatin	Atorvastatin	Statin	Sequence
	n = 28	n = 28	n = 28	effecta	effectb
Glycoalbumin (%)	17.1 ± 2.5	17.0 ± 2.8	17.6 ± 3.2	<0.01	0.71
Fasting blood glucose (mmol/L)	7.28 ± 1.88	6.70 ± 1.20	7.38 ± 1.71	<0.01	0.18
Insulin (pmol/L)	59.3 ± 39.5	44.6 ± 30.8	47.2 ± 28.8	0.42	0.54
HOMA‐IR (mmol/L)	2.92 ± 2.31	1.89 ± 1.24	2.29 ± 1.64	0.03	0.78
Body mass index (kg/m2)	25.1 ± 4.2	25.2 ± 4.0	25.3 ± 4.2	0.38	0.99
Systolic BP (mmHg)	132.1 ± 14.1	127.6 ± 13.4	132.0 ± 17.3	0.08	0.59
Diastolic BP (mmHg)	73.6 ± 11.3	70.9 ± 10.1	72.7 ± 9.7	0.13	0.09
Total cholesterol (mmol/L)	4.58 ± 0.50	4.71 ± 0.69	4.75 ± 0.69	0.70	0.72
HDL‐C (mmol/L)	1.52 ± 0.28	1.54 ± 0.33	1.54 ± 0.37	0.94	0.71
LDL‐C (mmol/L)	2.57 ± 0.24	2.65 ± 0.50	2.63 ± 0.39	0.82	0.55
Triglyceride (mmol/L)	1.26 ± 0.44	1.29 ± 0.52	1.26 ± 0.58	0.73	0.91
AST (U/L)	22.7 ± 6.9	23.6 ± 6.9	24.1 ± 7.3	0.63	0.10
ALT (U/L)	22.9 ± 10.4	24.3 ± 11.1	27.0 ± 17.2	0.22	0.19
Creatine kinase (U/L)	99.8 ± 69.7	120.3 ± 82.7	133.2 ± 100.5	0.31	0.80
Adiponectin (mg/L)	12.2 ± 8.0	12.2 ± 7.0	12.2 ± 7.7	0.97	0.25
hs‐CRP (mg/L)	0.68 (0.36–0.93)	0.55 (0.25–1.32)	0.56 (0.31–0.98)	0.81	0.86

Data are mean ± standard deviation. The median highly‐sensitive C‐reactive protein (hs‐CRP) values are shown (range 25–75%). The log transformed hs‐CRP values were applied to the mixed effect model.

^aComparison between pitavastatin and atorvastatin treatments by mixed effect model.

^bComparison between the two sequences by mixed effect model.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostasis model assessment of insulin resistance; LDL‐C, low‐density lipoprotein cholesterol.